ATXN3 and non-small cell lung carcinoma: Previous studies have shown that sensitivity to PD-1 blockade in patients with advanced NSCLC was enhanced in tumors enriched for clonal neoantigens; it will be interesting to analyze the effect of ATXN3 suppression on neoantigen presentation as reported (52).